|
STATE OF THE ART
MANUFACTURING FACILITY RELISYS MEDICAL DEVICES LTD, HYDERABAD
INAUGURAL ADDRESS BY PRESIDENT Dr A. P. J. Abdul Kalam
I am delighted to participate
in the inauguration of Cardiac stent manufacturing facility at Relisys Medical
Devices Ltd (RMDL) at Hyderabad. My greetings to Prof Soma Raju, Dr. Krishna
Reddy, cardiac specialists, scientists, technologists, clinicians,
pharmaceutical personnel and distinguished guests. Since RMDL is in the business
of medical devices and systems particularly the stent which is indeed a highly
competitive product for a great societal mission. I would like to share with you
my thoughts on competitiveness.
Law of Development
I was studying the development patterns and the dynamics of connectivity between
nations, especially in trade and business. As you all know the world has few
developed countries and many developing countries. What is the dynamics between
them and what connects them? Developed country has to market their products in a
competitive way to different countries to remain as developed country. For the
developing country to get transformed into developed country, they too have to
market their products to other countries in a competitive way. Competitiveness
is the common driving factors between the two types of nations. Competitiveness
has three dimensions: quality of the product, cost effectiveness and product is
in the market just-in-time. Indeed this dynamics of competitiveness is a common
factor between developing country and a developed country. There is a
relationship between the core competence and the competitiveness of the country.
Innovation is the capital that promotes competitiveness. For a country like
India with huge untapped market potential in health care products, innovative
methods of making the state-of-the-art products available at affordable costs
for different segments of society call for unique strategies.
Innovation is the capital
I was studying the Global Competitiveness Report for the year 2006-07. There I
find in terms of Growth Competitive Index ranking Switzerland is ranked 1,
Finland is ranked 2, Singapore is ranked 5, US is ranked 6, Korea 24, UAE 32,
India 43 and China 54. I am glad to find that India has moved up in
competitiveness to 43. Some time back, the President of Finland, Her Excellency
Mrs. Tarja Halonen, visited Rashtrapati Bhavan. During the discussion, I asked
the President of Finland, what is the significance and how Finland is always in
the first few positions in the competitiveness index during the last few years.
She gave three reasons: (1). Education, Education, Education - it is the
foundation for the Finland's Competitiveness, (2). Life Long learning is
promoted in Finland - people continuously are in learning mode, (3). Women are
empowered with Education. Of course we have similar experience in the country,
wherever we have empowered the women with education, they have excelled in Human
Development Index. Growth competitiveness is determined by the innovative
ability of any institution or organization. This innovation arises from
institutional initiative and the R & D productivity of the firm. Innovation is
the prime mover for engineering design, engineering development, value addition
and production.
Strategies for enhancing
competitiveness
Even though there is a potential to increase the demand, market for Stents,
demand will always be for the best available stent from the patient angle.
Particularly for Indian companies, it is all the more important to face multiple
challenges including from foreign manufacturers. For meeting the competitiveness
of the products like stents, it is important to build a database of all the
supplied stents by your company. And establish product quality over a period of
time. In addition continuous research has to be the focus to bring down the cost
at increased quality. Fortunately, Relisys Medical Devices Ltd at Hyderabad
derives clinical data base from CARE hospital. Above all, it is essential to
bring the confidence among the Indian patients that stents manufactured by the
RMDL are comparable to the imported stents though its cost is much lower.
Continuous technology flow on manufacturing, continuous improvement of design
inputs from cardiologists and patients are important factors for improving
competitiveness in the market.
Strength through partnership
I am happy that RMDL is exploring the possibility of contract manufacturing for
international players. This will not only enhance the quality of the product due
to the stringent quality requirement of the international company, it will also
increase the capacity utilization of the plant. The aim of Relisys should be to
market stents and catheters and medical disposables at half the price of its
competitors while maintaining high quality and higher profit margin through
higher volume of sale. This will involve expanding R & D strengths in
metallurgy, drug delivery and evaluation by creating linkages with educational
institutions and national R & D laboratories.
Conclusion
"Today, research in stents has to be to compare different types of DES, and also
between the newer kinds of drug combinations to be coated on stents to find a
solution to the problem of late stent thrombosis". The ideal stent should be
completely inert, not activate the clotting system and will disappear after a
given period. Is it possible? You experts can make it possible.
With these words, I inaugurate the Cardiac stent manufacturing facility at
Relisys Medical Devices. My best wishes to the Relisys team for success in their
mission of providing an ideal cardiac stent to the cardiac patients at an
affordable cost.
May God bless you.
Ref:- http://pib.nic.in/release/release.asp?relid=28891
|
|
